A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)
					AJX-101 is a first-in-human (FIH), phase 1, non-randomized, multi-center, open-label
clinical trial designed to investigate the safety, tolerability, pharmacokinetics (PK),
clinical activity and changes in biomarkers of an orally administered type II JAK2
inhibitor, ...
					
						
							
						
						
							
								
									
										Age: 18 years - 66+
									
								
								
									
										Gender: All
									
								
							 
						
					 
				
			
				
					Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera
					The goal of this clinical trial is to compare the efficacy and safety of givinostat to
hydroxyurea in Jak2V617F-positive high risk polycythemia vera patients.
					
						
							
						
						
							
								
									
										Age: 18 years - 66+
									
								
								
									
										Gender: All
									
								
							 
						
					 
				
			
				
					Study to Assess SLN124 in Patients With Polycythemia Vera
					This is a Phase 1/2, multicenter study with an open-label dose escalation followed by a
 randomized placebo controlled and double-blind phase of SLN124 in adult patients with
 Polycythemia Vera (PV) to assess the safety, tolerability, efficacy, pharmacokinetic (PK),
...
					
						
							
						
						
							
								
									
										Age: 18 years - 66+
									
								
								
									
										Gender: All
									
								
							 
						
					 
				
			
				
					Study of DISC-0974 in Participants with Myelofibrosis or Myelodysplastic Syndrome and Anemia
					This phase 1b/2a open-label study will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of DISC-0974 as well as categorize the effects on anemia response in subjects with myelofibrosis or myelodysplastic syndrome and anemia.
					
						
							
						
						
							
								
									
										Age: 18 years - 66+
									
								
								
									
										Gender: All
									
								
							 
						
					 
				
			
				
					To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)
					The purpose of the study is to compare the efficacy of parsaclisib when combined with
 ruxolitinb versus placebo combined with ruxolitinib in participants with myelofibrosis.
					
						
							
						
						
							
								
									
										Age: 18 years - 66+
									
								
								
									
										Gender: All
									
								
							 
						
					 
				
			
				
					Hepcidin Mimetic in Patients With Polycythemia Vera
					This is a Phase 2 study with an open-label dose escalation phase followed by a blinded
 withdrawal phase and an open label extension. The study is designed to monitor the PTG-300
 safety profile and to obtain preliminary evidence of efficacy of PTG-300 for the treatme...
					
						
							
						
						
							
								
									
										Age: 18 years - 66+
									
								
								
									
										Gender: All
									
								
							 
						
					 
				
			
				
					A Safety Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib With Concomitant Luspatercept for Subjects With Anemia
					This is Single-Arm, Open-Label Efficacy and Safety Trial of Fedratinib in Subjects with DIPSS
 (Dynamic International Prognostic Scoring System)-Intermediate or High- Risk Primary
 Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (post-PV MF), or Post-Essenti...
					
						
							
						
						
							
								
									
										Age: 18 years - 66+
									
								
								
									
										Gender: All
									
								
							 
						
					 
				
			
				
					A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
					This study (study ID PAC203 North America; PAC303 ex-North America) is evaluating 200 mg
BID of pacritinib compared to physician's choice (P/C) therapy in patients with MF and
severe thrombocytopenia (platelet count <50,000/μL). Approximately 399 patients in total
wi...
					
						
							
						
						
							
								
									
										Age: 18 years - 66+
									
								
								
									
										Gender: All
									
								
							 
						
					 
				
			
				
					PD-1 Inhibition in Advanced Myeloproliferative Neoplasms
					The purpose of this study is to test the effectiveness of a drug called pembrolizumab in
 patients with Myeloproliferative Neoplasm (MPN); chronic phase (MF-CP), accelerated phase
 (MPN-AP), or blast phase (MF-BP). Myelofibrosis neoplasm (MPN) is a group of diseases of ...
					
						
							
						
						
							
								
									
										Age: 18 years - 66+
									
								
								
									
										Gender: All
									
								
							 
						
					 
				
			
				
					Research Tissue Bank 
					This study that will allow for the preservation and/or storage of a small portion one or more of the following tissues: - Peripheral blood - Bone marrow - Bone marrow biopsy - A phlebotomized unit of blood - Spleen cells - Toenail clippings This material will be used fo...
					
						
							
						
						
							
								
									
										Age: 18 years - 66+
									
								
								
									
										Gender: All
									
								
							 
						
					 
				
			
				
					Correlative Biomarker Study in Patients With Myeloproliferative Disorders
					Researchers will use abnormal blood and/or bone marrow cells, or materials derived from these abnormal cells, like DNA, RNA, protein or plasma, in laboratory studies. Toenail clippings will provide normal material like DNA for comparison with the abnormal material deriv...
					
						
							
						
						
							
								
									
										Age: 18 years - 66+
									
								
								
									
										Gender: All